How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) released its quarterly earnings data on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million.

When did GenVec's stock split?

GenVec's stock reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of GenVec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GenVec investors own include Sarepta Therapeutics (SRPT) , Alibaba Group (BABA) , NVE (NVEC) , Microbot Medical (MBOT) , Pluristem Therapeutics (PSTI) , Acer Therapeutics (ACER) , Chesapeake Energy (CHKAQ) , MicroVision (MVIS) and Stone Energy (SGY) .

NASDAQ:GNVC

GenVec (GNVC) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free GNVC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $7.19
▼
$7.19
50-Day Range: N/A
52-Week Range: $2.70
▼
$10.44

Volume: N/A
Average Volume: 259,136 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get GenVec alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About GenVec Stock (NASDAQ:GNVC)

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

GNVC Stock News Headlines

December 18, 2023 | dailymail.co.uk

Cold virus can hunt down cancer

November 7, 2023 | morningstar.com

Huangshan Novel Co Ltd Class A 002014

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

February 20, 2023 | thestreet.com

GenVec Stock Hit by Pancreas Study's Details

January 3, 2023 | thestreet.com

Early Volume Plays: Novavax, GenVec

December 18, 2022 | thestreet.com

GenVec Value Slammed on Drug Failure

See More Headlines

Receive GNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GenVec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2016
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:GNVC
CUSIP: N/A
CIK: 934473
Web: www.genvec.com
Phone: +1-240-6320740
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Wayne T. Hockmeyer Ph.D.
Independence Chairman of the Board
Douglas J. Swirsky
President, Chief Executive Officer, Corporate Secretary, Director
William N. Kelley M.D.
Independent Director
Stefan D. Loren Ph.D.
Independent Director
Quinterol J. Mallette M.D.
Independent Director
Michael S. Richman
Independent Director
Marc R. Schneebaum
Independent Director

GNVC Stock Analysis - Frequently Asked Questions

How were GenVec's earnings last quarter?: GenVec Inc (NASDAQ:GNVC) released its quarterly earnings data on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million.
When did GenVec's stock split?: GenVec's stock reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of GenVec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GenVec investors own include Sarepta Therapeutics (SRPT), Alibaba Group (BABA), NVE (NVEC), Microbot Medical (MBOT), Pluristem Therapeutics (PSTI), Acer Therapeutics (ACER), Chesapeake Energy (CHKAQ), MicroVision (MVIS) and Stone Energy (SGY).

This page (NASDAQ:GNVC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GenVec (GNVC) Stock Price, News & Analysis

About GenVec Stock (NASDAQ:GNVC)

GNVC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

GNVC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info